Acertis Pharmaceuticals Gains Regulatory Momentum with Levorphanol Tartrate Application
Pain Management · Opioid • Regulatory Approval • Jun 24, 2026
Assessment confidence: 89% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
Executive Thesis
The FDA's acceptance of the supplemental application for Levorphanol Tartrate by Acertis Pharmaceuticals is significant as it positions Acertis to strengthen its foothold in the competitive opioid pain management market. This development necessitates close monitoring of market dynamics and potential responses from other manufacturers. Regulatory context from FDA (FDA AP — LEVORPHANOL TARTRATE (SUPPL)) supports the near-term read. Assessment grounded in 8 ranked evidence items (8 high-relevance).
Strategic Assessment
Portfolio teams should assess the potential market impact and prepare for competitive responses from other opioid manufacturers. The strongest clinical anchor is Clinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In rare disease, 8 regulatory and 0 competitive items passed relevance filtering for Acertis Pharmaceuticals.
Competitive Pressure
The most relevant competitive pressure comes from This acceptance may enhance Acertis' position in the pain management market, particularly in the opioid segment, where competition is intense..
Regulatory Outlook
Regulatory risk is concentrated around FDA AP — LEVORPHANOL TARTRATE (SUPPL) (FDA). Sub-indication match (rare disease); Entity match (levorphanol tartrate). The acceptance of this application indicates a positive regulatory trajectory, but further monitoring is required to understand the implications for market entry and compliance.
Key Risks
- Elevated medium regulatory exposure for Acertis Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.
Key Opportunities
- The approval could lead to increased market share for Acertis in the opioid segment, impacting revenue streams and competitive positioning against established players.
- Portfolio teams should assess the potential market impact and prepare for competitive responses from other opioid manufacturers.
What Would Change This Assessment
- This becomes more urgent if Monitor the timeline for approval and any subsequent market entry strategies from Acertis.
- Timeline shift beyond mid term would change urgency.
- A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.
Supporting Evidence
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Entity match (levorphanol tartrate)
FDA document
View sourceFDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Entity match (levorphanol tartrate)
FDA document
View sourceFDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Entity match (levorphanol tartrate)
FDA document
View sourceFDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View sourceFDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View sourceFDA AP — DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE (ORIG)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View sourceFDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View sourceFDA AP — AUVELITY (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source
Clinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceLow Dose Naltrexone Therapy for Complex Regional Pain Syndrome
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceComparison of Two Dosing Regimens of Intravenous Ketorolac for Post-Cesarean Pain Control
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceA Prospective Study to Evaluate the Efficacy of Iovera Lumbar Medial Branch Cryoneurolysis Versus Radiofrequency Ablation for the Treatment of Chronic Low Back Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceHuman Experimental Models of Pain (HEMP)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerlow relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Effects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceTwo-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceEffects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceThe application of growth factors in bone tissue engineering delivery systems and collaborative innovation strategies.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceFactors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Related Signals
Related Regulatory Precedents
FDA
FDA AP — AUVELITY (SUPPL)
Application NDA215430. Sponsor: AXSOME. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: BUPROPION HYDROCHLORIDE, DEXTROMETHORPHAN HYDROBROMIDE.
SourceFDA
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
Application ANDA075499. Sponsor: APOTEX. Submission status: AP. Submission type: SUPPL. Active ingredients: BUTORPHANOL TARTRATE.
SourceFDA
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
Application ANDA075824. Sponsor: HIKMA. Submission status: AP. Submission type: SUPPL. Active ingredients: BUTORPHANOL TARTRATE.
SourceFDA
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
Application ANDA074278. Sponsor: HIKMA. Submission status: AP. Submission type: SUPPL. Active ingredients: LEVORPHANOL TARTRATE.
SourceFDA
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
Application ANDA211484. Sponsor: ACERTIS PHARMS. Submission status: AP. Submission type: SUPPL. Active ingredients: LEVORPHANOL TARTRATE.
Source